FGP
LEGN icon

Freestone Grove Partners’s Legend Biotech LEGN Stock Holding History

Freestone Grove Partners’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Buy
+5,493
New +$148K ﹤0.01% 814

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Freestone Grove Partners's LEGN Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Legend Biotech (LEGN) in Q2 2026: 5,493 shares worth $159K. The stake represents ﹤0.01% of the portfolio and ranks #814 among its holdings.

218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Freestone Grove Partners held 5,493 shares of Legend Biotech worth $159K as of Q2 2026.
  • Legend Biotech was a new Freestone Grove Partners position in Q2 2026.
  • Legend Biotech made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #814 holding.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.